Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00162123 · ClinicalTrials.gov registry record · Phase 2
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Phase 2 study of Melanoma, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 248
- Enrollment target
- 20
- Study locations
NCT00162123: Completed Phase 2 study of Melanoma, sponsored by Bristol-Myers Squibb.
NCT00162123 is a Phase 2 study of Melanoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 248 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00162123, a Phase 2 study of Melanoma, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 248 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to evaluate the continued use of ipilimumab in patients who had reinduction at the time of disease progression or to continue maintenance treatment. In addition, this study will continue to follow patients who have taken ipilimumab, but who are not eligible for maintenance or reinduction therapy.
Primary Outcome
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. An SAE is a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Drug-related is defined as having certain, probable, possible, or missing relationshi
Conditions Studied
Interventions
- DRUG Ipilimumab
Study Locations (20)
California
- Wilshire Oncology Medical Group Inc - Laverne
- The Angeles Clinic & Research Inst. - Los Angeles
- Usc/Norris Comprehensive Cancer Center - Los Angeles
- San Francisco Oncology Associates - San Francisco
Missouri
- St Joseph Oncology Inc - Saint Joseph
- Washington University School Of Medicine - St Louis
Texas
- Center For Oncology Research & Treatment, P.A. - Dallas
- Joe Arrington Cancer Research And Treatment Center - Lubbock
Arizona
- University Of Arizona Cancer Center - Tucson
Connecticut
- Local Institution - To Come
Florida
- Baptist Cancer Institute - Jacksonville
Illinois
- University Of Chicago - Chicago
Indiana
- Indiana Oncology Hematology Consultants - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2006-05 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
What the finished NCT00162123 record still lists
NCT00162123 is an interventional study that assigns participants to a tested intervention. The registered 248 participants enrollment target is mid-sized for trials with a published cap, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Ipilimumab is the first listed.
NCT00162123 names 20 study sites across 15 states, led by California, Missouri, Texas.
Frequently Asked Questions
What is clinical trial NCT00162123 about?
NCT00162123 is a clinical study titled "A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies". The purpose of this study was to evaluate the continued use of ipilimumab in patients who had reinduction at the time of disease progression or to continue maintenance treatment. In addition, this study will continue to follow patients who have taken ipilimumab, but who are not eligible for maintena...
What is the current status of trial NCT00162123?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 248 participants. The study started on 2006-05. Estimated completion is 2014-04.
What conditions does trial NCT00162123 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT00162123?
The interventions under investigation include: Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT00162123?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00162123 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00162123's enrollment target sits among peer trials
248 62nd of 266 higher than 205 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04577911 · 248 participants
How is Social Connection Represented in the Brain?
- NCT04777994 · 248 participants · Phase 1
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- NCT04792489 · 248 participants · Phase 2
DALY II USA/ MB-CART2019.1 for DLBCL
- NCT04830137 · 248 participants · Phase 1
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia